Prior studies have documented that disparities exist in prostate cancer incidence, treatment, and outcomes among racial and ethnic minority groups. The recommendation for germline testing for a large proportion of men with prostate cancer has further exacerbated disparities in diverse patient populations. As genetic testing recommendations from National Comprehensive Cancer Network and other professional societies and expert panels evolve to include more patients, it is critical that urology, oncology, and genetics providers address existing gaps in care for an increasingly diverse population of prostate cancer patients. Expanding genetic testing uptake among racial and ethnic minorities may result in the detection of mutations that drive aggressive prostate cancer, the selection of systemic therapies, and cascade testing for family members. Each of these indications is thought to improve prostate cancer care and outcomes.